ALX Oncology (ALXO) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ALXO ALX Oncology

Watchlist

1.620
+0.140+9.46%

Close Dec 20 16:00 ET

1.620
-0.001-0.03%

Post 20:01 ET

85.44MMarket Cap-0.55P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Jefferies Downgrades ALX Oncology(ALXO.US) to Hold Rating, Cuts Target Price to $2
Moomoo NewsDec 20 12:32 ET · Ratings
Sector Update: Health Care Stocks Decline Late Afternoon
MT NewswiresDec 19 15:56 ET
Sector Update: Health Care
MT NewswiresDec 19 15:32 ET
ALX Oncology Shares Are Trading Lower After Jefferies Downgraded the Stock From Buy to Hold and Cut Its Price Target From $12 to $2.
BenzingaDec 19 15:31 ET
Top Midday Decliners
MT NewswiresDec 19 13:48 ET
Jefferies Downgrades ALX Oncology Holdings to Hold, Lowers Price Target to $2
BenzingaDec 19 07:08 ET · Ratings

Comments

Jaguar8

Dec 10 08:02

NEWS

$ALX Oncology (ALXO.US)$
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
Tuesday, 10th December at 9:00 am
Data from Phase 1b/2 clinical trial to be presented at 2024 San Antonio Breast Cancer Symposium (SABCS) show encouraging clinical activity in patients with heavily pretreated HER2-positive breast cancer who had received multiple HER2-targeted agents, including fam-trastuzumab deruxt...

Teddy123

Nov 3 22:40

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

$ALX Oncology (ALXO.US)$
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, today announced tha...

Jaguar8

Nov 1 16:31

NEWS

$ALX Oncology (ALXO.US)$
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
ALX Oncology (Nasdaq: ALXO) announced that results from their Phase 1b/2 trial combining evorpacept with zanidatamab in HER2-positive and HER2-low metastatic breast cancer will be presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2024. The presentation will showcase data from...